Conventional medical therapy in heart failure patients eligible for the PARADIGM-HF, DAPA-HF, and SHIFT trials
Shoji S, Kohsaka S, Shiraishi Y, Kohno T, Sawano M, Ikemura N, Niimi N, Nagatomo Y, Tanaka T, Takei M, Ono T, Sakamoto M, Nakano S, Nakamura I, Inoue S, Fukuda K, Yoshikawa T. Conventional medical therapy in heart failure patients eligible for the PARADIGM-HF, DAPA-HF, and SHIFT trials. International Journal Of Cardiology 2022, 359: 76-83. PMID: 35421518, DOI: 10.1016/j.ijcard.2022.04.020.Peer-Reviewed Original ResearchConceptsConventional medical therapyHF readmission ratesMedical therapy useMedical therapyLong-term outcomesEnrollment criteriaReadmission ratesTherapy useRecent trialsReduced ejection fractionHeart failure patientsHeart failure treatmentUse of BBsShift trialsDAPA-HFHF registryHFrEF patientsMulticenter registryPARADIGM-HFFailure patientsConsecutive patientsEjection fractionPatient subsetsPrescription ratesFailure treatment